Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
John Russel DentonSEE REMARKS | Caris Life SciencesCAI | Open-market sale | 09/22 | 09/23 | 7,500 sh | $31.82 | $238,626 | −4.1% |
Jeff L. VacircaDirector | Caris Life SciencesCAI | Open-market buy | 05/11 | 05/12 | 31,050 sh | $16.15 | $501,457.5 | +166.7% |
Caris Life SciencesCAI | Open-market sale10b5-1 plan | 25/12/11 | 25/12/12 | 62,250 sh2 trades | $26.57avg. | $1,654,200 | −38.5% | |
John Russel DentonSEE REMARKS | Caris Life SciencesCAI | Open-market buy | 25/11/07 | 25/11/10 | 4,184 sh | $24.09 | $100,792.56 | +83.7% |
David Baxley SpetzlerPresident | Caris Life SciencesCAI | Open-market buy | 25/11/07 | 25/11/10 | 400 sh | $23.85 | $9,540 | +0.1% |
John Russel DentonSEE REMARKS | Caris Life SciencesCAI | Open-market buy | 25/06/20 | 25/06/23 | 7,500 sh | $21.00 | $157,500 | +6.5% |
Brian J. BrilleSEE REMARKS | Caris Life SciencesCAI | Open-market buy | 25/06/20 | 25/06/23 | 30,000 sh | $21.00 | $630,000 | +22.7% |
